Typing of European strains of parvovirus B19 by restriction endonuclease analyses and sequencing: Identification of evolutionary lineages and evidence of recombination of markers from different lineages

Johansen, Jorunn N.; Christensen, Laurids Siig; Zakrzewska, K.; Carlsen, K. M.; Hornsleth, A; Azzi, Alberta

doi:10.1016/s0168-1702(97)00151-2

Cited by 15 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the present study, we focused on major regions of VP1 and VP2 encoding sequences based on the rationale that the NS1 encoding region is highly conserved among parvovirus species [20]. In addition, NS1 in parvovirus B19 does not elicit a detectable antibody response in acutely infected individuals [21] and, thus, might not be relevant in the context of an immunopathogenetic significance of strain diversity [20]. Therefore, we have analyzed the nucleotide and amino acid sequences of the VP1 unique region (ΔV) as well as the junction region (VP1/VP2) that were amplified from the patients infected in a single outbreak.…”

Section: Discussionmentioning

confidence: 99%

Genetic heterogeneity of the immunogenic viral capsid protein region of human parvovirus B19 isolates obtained from an outbreak in a pediatric ward

et al. 1999

View full text Add to dashboard Cite

Whereas human parvovirus B19 commonly infects children and causes erythema infectiosum, it causes more severe diseases when it infects adults. In order to examine whether different clinical outcomes of B19 infection can be ascribed to the viral genetic heterogeneity, we have determined the nucleotide sequence of highly immunogenic portions of the B19 genome obtained from six patients with various clinical manifestations in a single outbreak. Our observations demonstrated that although the B19 sequences showed a significant heterogeneity, it was not correlated with the clinical manifestation. It was thus suggested that the host immune response to B19 infection may be a major determinant of clinical presentations associated with acute B19 infection.z 1999 Federation of European Biochemical Societies.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic heterogeneity of the immunogenic viral capsid protein region of human parvovirus B19 isolates obtained from an outbreak in a pediatric ward

et al. 1999

View full text Add to dashboard Cite

show abstract

“…It was considered the only human pathogen of this family until the discovery of the new human parvoviruses PARV4, PARV5 and human bocavirus [Allander et al, 2005;Jones et al, 2005;Fryer et al, 2006]. For a long time, the B19 DNA sequence was considered highly stable, with a variation of 1-2% [Hemauer et al, 1996;Johansen et al, 1998]. Recently, some variants have been described, whose overall sequences differ from the prototype and from each other by approximately 10%.…”

Section: Introductionmentioning

confidence: 99%

Tissue persistence of parvovirus B19 genotypes in asymptomatic persons

Corcioli

Zakrzewska

Rinieri

et al. 2008

Journal of Medical Virology

View full text Add to dashboard Cite

Parvovirus B19 (B19V) can persist in immunocompetent symptomatic and non-symptomatic individuals, as demonstrated by the finding of viral DNA in different tissues, in absence of viremia and of anti-B19V IgM. The spread and the nature of this phenomenon have not been clearly determined. In order to investigate the frequency of persistence and the tissue distribution of the three genotypes of B19V, the viral load of the persistent virus and its expression in the affected tissues, 139 tissue samples and 102 sera from 139 asymptomatic individuals have been analyzed by consensus PCRs and genotype specific PCRs for B19V detection and genotyping. Viral load was measured by real time PCR and viral mRNAs were detected by RT-PCR. Altogether, 51% individuals carried B19V DNA, more frequently in solid tissues (65%) than in bone marrow (20%). Genotype 1 was found in 28% tissue samples, genotype 2 in 68% and genotype 3 in 3% only. Viral load ranged from less then 10 copies to 7 x 10(4) copies per 10(6) cells, with the exception of two samples of myocardium with about 10(6) copies per 10(6) cells. mRNA of capsid proteins was present in two bone marrow samples only. In conclusion, in asymptomatic individuals B19V persistence is more common in solid tissues than in bone marrow, and genotype 2 persists more frequently than genotype 1. The results suggest that the virus persists without replicating, at sub-immunogenic levels.

show abstract

“…Transcription produces at least nine overlapping messenger RNA transcripts, all initiated from the single P6 promotor at the extreme left side of the genome (275). conserved through evolutionary lineages were found (164) and chronic infections provide the opportunity of coexistence of and recombination between strains of various phylogenetic origin (164). The NS1 is well conserved among most isolates, consistent with its required role in virus propagation, while VP1 and VP2 regions occasionally may show a greater variability of 2-3% (151,232).…”

Section: Ivi2 Physical and Chemical Characteristicsmentioning

confidence: 93%

“…Furthermore, epidemiological studies of patients with parvovirus B19 DNA positive serum samples can be carried out with a combination of restriction enzyme analysis (REA) of PCR 27 products and sequencing to identify and evaluate the stability of genetic markers conserved through evolutionary lineages (164). The incidental findings by sequencing of identical point deviations causing the various gross fragment patterns regardless of time, of isolation and country of origin, strongly substantiates that such markers did not randomly appear in different evolutionary lineages.…”

Section: Vi9 Diagnostic Methods For Parvovirus B19mentioning

confidence: 99%

“…Introduction - Taxonomy Appendix 3,5,6,7,9,10), two English articles (Appendix 4 and 8) (154,164) and some of the photos have been shown in Danish articles (Appendix 1 and 2) (41,42,44,155) and a booklet (43) to help other health-care professionals to recognise human parvovirus B19 infection in clinical practice and thus prepare samples for diagnostic purposes to ensure necessary, timely treatment.…”

Section: IVmentioning

confidence: 99%

See 1 more Smart Citation